At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 21 target
Drug / intervention
BL-B16D1drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Preliminary Efficacy of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors
In Brief
A Phase 1 clinical trial evaluating BL-B16D1 for Solid Tumor. Currently recruiting, targeting 21 participants across 1 site.
Detailed Summary
This study is an open, multicenter, dose-escalation and expansion-enrollment and nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-B16D1 in locally advanced or metastatic solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesChina
CollaboratorsBaili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Timeline
Phase 1RecruitingOverdue
20252026
First PostedJun 2024
Enrollment StartJul 2024
Primary CompletionJul 2026
TodayJul 2026
First PostedJun 26, 2024
Enrollment StartJul 18, 2024
Primary CompletionJul 1, 2026
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 2.0 years ago
Interventions
BL-B16D1drug
Administration by intravenous infusion for a cycle of 3 weeks.